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Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis.1 AML is thought to 
be initiated and maintained by a rare population of leukemia stem cells  (LSCs) or leukemia-initiating 
cells (LICs) that have acquired the capacity for self-renewal and is blocked in their ability to differentiate 
by the accumulation of a series of mutations and/or epigenetic changes.2-3 Clinical studies show that LICs 
are resistant to conventional chemotherapy and/or targeted therapies.3 Thus, there is an unmet need to 
elucidate the molecular mechanisms governing LIC self-renewal and develop novel therapeutic 
approaches that can target LICs and improve leukemia treatment.3 
 The tumor suppressor p53 is a stress response protein that regulates a large number of genes in 
response to a variety of cellular insults, including oncogene activation, DNA damage and inflammation.4 
These signals activate p53 primarily through post-translational modifications that result in augmented 
levels of p53 protein and transactivation activity.4 Activated p53 suppresses cellular transformation 
mainly by inducing growth arrest, apoptosis, DNA repair and differentiation in damaged cells.4 
Accordingly, p53 function is always compromised in tumor cells, usually as a result of somatic mutations 
and deletions, which occur in approximately half of all human cancers.5 The TP53 gene encodes the 
tumor suppressor p53. The frequency of TP53 mutations in AML is approximately 10%. However, in 
AML with complex karyotype, the frequency of TP53 mutations and/or deletions is almost 70%.6 While 
TP53 mutations confer drug resistance and poor prognosis in AML, the role of mutant p53 in the initiation 
and progression of AML is largely unknown.6-7 
 We have been investigating the role of tumor suppressor p53 in normal and malignant 
hematopoiesis. We found that wild type p53 maintains HSC quiescence and inhibits HSC self-renewal.8  
Codon 248 of p53 is frequently mutated in AML and p53R248W has been shown to be a gain-of function 
(GOF) mutant in human cancer cells as well as in animal models.6-7, 9 We recently reported that p53R248W 
enhances HSC self-renewal in steady state and promotes HSC expansion following genotoxic stresses.10 
Of note, homozygous p53-/- and p53R248W/R248W mice develop lymphoid tumors, including lymphoma and 
thymoma, but not myeloid malignancies,9 suggesting that expression of mutant p53 is not sufficient for 
 
 
inducing myeloid leukemia in mice. This has led to a search for potential second hits that cooperate with 
mutant p53 in the pathogenesis of myeloid malignancies, primarily focused on using mouse models.  
 While coexisting mutations with TP53 mutations in AML are limited,6-7 previous studies indicate 
that TP53 mutations co-occur with AML driver mutations in oncogenic signaling molecules such as FMS-
like tyrosine kinase receptor-3 (FLT3).11  Mutations in FLT3 have been identified in myeloid 
malignancies, including myeloproliferative neoplasms (MPN) and AML.12 Internal tandem duplications 
in the juxtamembrane domain (FLT3-ITD) and mutations in the activating loop of FLT3 (FLT3-TKD) are 
seen in 30 to 35% of AML patients.12 Both ITD and TKD mutations of FLT3 lead to constitutive activation 
of the tyrosine kinase, promoting proliferation and survival of leukemic blasts.12 Given that expression of 
FLT3-ITD in the hematopoietic compartment results in MPN in mice and that FLT3-ITD impairs HSC 
self-renewal in vivo,13 we reasoned that mutant p53 might synergize with FLT3-ITD in driving the 
development of myeloid leukemia through enhancing LIC self-renewal.  
 To test this hypothesis, we generated p53R248W/+FLT3ITD/+ mice and monitored overall survival and 
tumor development of these mice. We observed that both FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice have 
decreased life span compared to p53+/+ mice (Figure 1a). Some p53R248W/+ mice develop myelodysplastic 
syndromes (MDS) with age and other p53R248W/+ mice developed lymphoma and sarcoma based upon 
pathological analysis of bone marrow (BM), spleen, liver, and peripheral blood (PB) (S.C. and Y.L., 
unpublished data). However, the majority of p53R248W/+FLT3ITD/+ mice developed MPN as seen in 
FLT3ITD/+ mice (Figures 1b, 1c and data not shown), suggesting that FLT3-ITD-induced MPN 
development does not depend on mutant p53. Histological observation of spleen sections from MPN mice 
showed disarray of normal splenic architecture with a reduction and almost total absence of the white pulp 
in some cases and increased red pulp area with increased extramedullary hematopoiesis (Figure 1c).   
These features appeared in conjunction with hepatosplenomegaly, variable leukocytosis and 
overproduction of myeloid cells in bone marrow, spleen and peripheral blood (Figure 1c). We noted that 
bone marrow cellularity decreased as splenomegaly increased, consistent with increased extramedullary 
hematopoiesis. Notably, approximately 25% of p53R248W/+FLT3ITD/+ mice developed chronic myeloid 
 
 
leukemia (CML).14 Upon necropsy, mice with CML displayed severe splenomegaly, and some also 
displayed hepatomegaly. Morphological analysis of peripheral blood smears revealed increased myeloid 
cells with dysplastic features (Figure 1c).  Bone marrow cellularity varied from hypocellular to 
hypercellular among animals. Increased number of myeloid cells (blast to immature myeloid cells) was 
observed in bone marrow with extensive spread of myeloid elements in spleen and in a few livers (Figure 
1c). While p53R248W/+FLT3ITD/+ mice showed marked splenomegaly compared to p53+/+ and FLT3ITD/+ 
mice (Figure 1d), this is not likely due to CML development as majority of double-mutant mice developed 
MPN (Figures 1b and 1c). 
Given that patients with homozygous FLT3-ITD mutations have a more severe disease compared 
to those with heterozygous FLT3-ITD mutations,11-12 we examined whether mutant p53 cooperates with 
homozygous FLT3-ITD mutant in leukemia development.  We transplanted 3 x 106 whole bone marrow 
cells from p53+/+, FLT3ITD/ITD, or p53R248W/+FLT3ITD/ITD mice into lethally irradiated recipient mice and 
measured their overall survival. Both FLT3ITD/ITD and p53R248W/+FLT3ITD/ITD recipient mice had decreased 
life spans compared to p53+/+ recipient mice (Figure S1a).  Interestingly, approximately 30% of the 
p53R248W/+FLT3ITD/ITD transplanted animals developed CML (Figure S1b), similar to that seen in 
p53R248W/+FLT3ITD/+ animals (Figure 1b). Rest of the p53R248W/+FLT3ITD/ITD mice developed MPN (Figure 
S1b).   
Given that some p53R248W/+FLT3ITD/+ mice develop CML, we next examined the impact of mutant 
p53 on FLT3-ITD+ hematopoietic stem and progenitor cells (HSPCs) in order to understand the underlying 
mechanisms. We first analyzed peripheral blood (PB), bone marrow (BM), and spleen of p53+/+, 
p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice (8 to 12 week-old). PB white blood cell (WBC) 
counts, BM cellularity, and spleen weight were comparable among the four groups of mice (Figures S1c, 
S1d, and S1e). We then examined the frequency of hematopoietic stem and progenitor cells in the BM of 
p53R248W/+FLT3ITD/+ mice. While the number of LT-HSCs and ST-HSCs was comparable among these 
mice, LSKs and MPPs were expanded in the p53R248W/+FLT3ITD/+ mice compared with that of the p53+/+, 
p53R248W/+ and FLT3ITD/+mice (Figure S2a). We also observed increased frequency of myeloid progenitors 
 
 
(Lin-Kit+ cells) in the bone marrow of p53R248W/+FLT3ITD/+ mice (Figure S2b). These findings suggest that 
the effects of mutant p53 and FLT3-ITD on myeloid progenitor cell expansion appears additive. However, 
the number of common lymphoid progenitors (CLPs) was comparable among four group of mice (Figure 
S2c).  
 FLT3 mutations have been show to enhance the proliferation of hematopoietic stem and progenitor 
cells.13 We then examined the cell cycle status of LSKs isolated from p53+/+, p53R248W/+, FLT3ITD/+ and 
p53R248W/+FLT3ITD/+ mice. We confirmed that FLT3ITD/+ LSKs shown enhanced proliferation compared 
with p53+/+ LSKs (Figure S2d). However, mutant p53 did not alter the proliferation of FLT3ITD/+ LSKs 
(Figure S2d). To determine the impact of mutant p53 on myeloid progenitors, we performed serial 
replating assays using BM cells from p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice. While 
the colony formation potential of p53+/+ and FLT3ITD/+ BM cells was comparable in serial replating assays, 
p53R248W/+FLT3ITD/+ BM cells show enhanced replating potential compared to p53R248W/+ and FLT3ITD/+ 
BM cells (Figure 2a), suggesting that expanded myeloid progenitors in p53R248W/+FLT3ITD/+ mice are 
functional in vitro.  
 To examine the impact of mutant p53 on HSCs in vivo, we performed serial competitive bone 
marrow transplantation assays. We transplanted 5 x 105 donor BM cells (p53+/+, p53R248W/+, FLT3ITD/+ or 
p53R248W/+FLT3ITD/+, CD45.2+) into lethally irradiated (11 Gy) F1 recipient mice (CD45.1+CD45.2+) along 
with 5 x 105 competitor BM cells (CD45.1+). Peripheral blood white blood cell counts were comparable 
among the four groups of mice following transplantation (Figure S2e). While FLT3ITD/+ BM cells showed 
decreased repopulating ability compared to p53+/+ cells 16 weeks post transplantation, 
p53R248W/+FLT3ITD/+ BM cells displayed enhanced engraftment compared to FLT3ITD/+ BM cells (Figure 
2b). We then sacrificed the recipient mice and examined the frequency of donor-derived hematopoietic 
stem and progenitor cells in their bone marrow. We found increased number of donor-derived LSKs in 
the BM of recipient mice repopulated with p53R248W/+ BM cells compared to that of the p53+/+ and 
FLT3ITD/+ BM cells, whereas the frequency of donor-derived LSKs in the BM of recipient mice 
repopulated with p53R248W/+ and p53R248W/+FLT3ITD/+ cells was comparable (Figure S2f). We found 
 
 
increased number of donor-derived GMPs in the BM of recipient mice repopulated with 
p53R248W/+FLT3ITD/+ bone marrow cells compared to that of the FLT3ITD/+ BM cells (Figure S3a). The 
spleen size was comparable in recipient mice repopulated with four group of BM cells (Figure S3b).  
 To determine the impact of mutant p53 on the self-renewal potential of FLT3-ITD+ HSCs, we  
transplanted 3 x 106 BM cells isolated from the primary recipient mice repopulated with p53+/+, p53R248W/+, 
FLT3ITD/+ or  p53R248W/+FLT3ITD/+ cells into lethally irradiated secondary F1 recipients. Sixteen weeks 
after transplantation, p53R248W/+FLT3ITD/+ cells continued to show increased repopulating ability compared 
to FLT3ITD/+ BM cells (Figure 2c). These findings suggest that mutant p53 may promote leukemic 
transformation through enhancing LIC self-renewal.   
 To examine the impact of mutant p53 on oncogenic signaling pathways, we performed western blot 
analysis on macrophage progenitor cells derived from p53+/+, p53R248W/+, FLT3ITD/+ or 
p53R248W/+FLT3ITD/+ bone marrow cells.  Consistent with previous studies, cells from FLT3ITD/+ mice had 
activated FAK, STAT5, and AKT (Figure 2d). Further, expressing FLT3-ITD in a mutant p53 background 
enhances activated ERK levels but slightly decreases activated FAK and STAT5 levels (Figure 2d). We 
found increased levels of FLT3 in p53R248W/+FLT3ITD/+ macrophage progenitor cells (Figure S3c). Thus, 
expressing FLT3-ITD in a mutant p53 background has no effect on FLT3-ITD-induced activation of 
signaling pathways. However, ERK inhibitor treatment decreased the replating potential of p53R248W/+, 
FLT3ITD/+ and p53R248W/+FLT3ITD/+ bone marrow cells (Figure S3d). These findings suggest that mutant 
p53 and FLT3-ITD may function through different signaling pathways in the pathogenesis of 
hematological malignancies.  In the future, we will elucidate the mechanisms by which mutant p53 
upregulates FLT3 in HSPCs. 
 While TP53 and FLT3 mutations are rarely co-occur in MPN and AML,11 the underlying 
mechanisms are not known.  We found that the majority of p53R248W/+FLT3ITD/+ mice developed MPN, as 
seen in FLT3ITD/+ mice.13 Further, we discovered that mutant p53 and FLT3-ITD cooperate in CML 
development in mice. Functionally, mutant p53 synergizes with FLT3-ITD to expand the myeloid 
progenitor cell pool and enhance the self-renewal potential of LICs. TP53 mutations are present in both 
 
 
chronic and blast crisis phase of CML,15 underscoring the importance of mutant p53 in CML pathogenesis. 
Delineating the role of mutant p53 and FLT3-ITD in LIC self-renewal and pathogenesis of hematological 
malignancies may facilitate the development of novel therapeutic approaches that can improve leukemia 
treatment. 
 
CONFLICT OF INTEREST 
The authors declared that no conflicts of interest exists. 
ACKNOWLEDGEMENTS 
This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through 
the Bone Marrow Failure Research Program - Idea Development Award under Award No. W81XWH-18-
1-0265 to YL. Opinions, interpretations, conclusions and recommendations are those of the author and 
are not necessarily endorsed by the Department of Defense. This work was also supported in part by two 
NIH R56 Awards (R56DK119524-01 and R56AG05250), a DoD Career Development Award W81XWH-
13-1-0187, a Scholar Award from the St. Baldrick’s Foundation, an Elsa Pardee Foundation New 
Investigator Award, a Leukemia Research Foundation New Investigator Award, a Showalter Trust Fund 
New Investigator Award, an Alex Lemonade Stand Foundation grant, a Children’s Leukemia Research 
Association grant, and an American Cancer Society Institutional Research Grant to YL. SCN was 
supported by a NIH F32 Award 1F32CA203049-01. The authors would like to acknowledge the 
Flow Cytometry Core and In vivo Therapeutic Core Laboratories, which were sponsored, in part, by the 
NIDDK Cooperative Center of Excellence in Hematology (CCEH) grant U54 DK106846. This work was 
supported, in part, by a Project Development Team within the ICTSI NIH/NCRR Grant Number 
UL1TR001108. We would like to thank Dr. Yang Xu at USCD for providing the p53R248W mice to the 
study.  
 
 
 
 
 
AUTHOR CONTRIBUTIONS 
SCN and YL Designed the research. SCN, SC, RG, CY, MK, SV, ACF, CW, and CD Performed the 
research. SCN, SC, and YL Analyzed the data and performed the statistical analysis. GES Performed 
pathological analysis. HSB, LDM, and RK Provided reagents and constructive advice to the study. SCN, 
SC, and YL Wrote the manuscript. All authors read, commented on, and approved the manuscript. 
 
 
REFERENCES 
1. Coombs CC, Tallman MS, Levine RL. Molecular therapy for acute myeloid leukaemia. Nat Rev Clin 
Oncol 2016;13:305-18.  
2. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell 
classes that differ in self-renewal capacity. Nat Immunol 2004; 5:738-43. 
3. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010; 
4: 443-50.  
4. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical 
efficacy. Nat Rev Drug Discov 2014; 13:217-36.  
5. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev 
Cancer 2009; 9:701-13. 
6. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H et al. TP53 alterations in acute 
myeloid leukemia with complex karyotype correlate with specific copy number alterations, 
monosomal karyotype, and dismal outcome. Blood 2012; 119: 2114-21. 
7. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute 
myeloid leukemia: projections on diagnostic workup and therapy. Blood 2017;130:699-712.  
8. Liu Y, Elf SE, Miyata Y, Sashida G, Liu YH, Huang G et al. p53 Regulates Hematopoietic Stem 
Cell Quiescence. Cell Stem Cell 2009; 4: 37-48. 
9. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by 
inactivating ATM. Nat Cell Biol 2007; 15: 376-88. 
10. Chen S, Gao R, Yao C, Kobayashi M, Liu SZ et al.  Genotoxic stresses promotes the clonal 
expansion of hematopoietic stem cells expressing mutant p53. Leukemia 2018; 32:850-854. 
11. Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S et al. Profiling of 
somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood 
2015;126:2491-501.  
 
 
12. Swords R, Freeman C, Giles F.  Targeting the FMS-like tyrosine kinase 3 in acute myeloid 
leukemia. Leukemia 2012; 26:2176-85. 
13. Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N et al. FLT3 mutations confer enhanced 
proliferation and survival properties to multipotent progenitors in a murine model of chronic 
myelomonocytic leukemia. Cancer Cell 2007;12:367-80. 
14. Morse HC 3rd, Anver MR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Jaffe ES, Kogan 
SC, MacLennan IC, Pattengale PK, Ward JM; Hematopathology subcommittee of the Mouse 
Models of Human Cancers Consortium. Bethesda proposals for classification of lymphoid 
neoplasms in mice. Blood 2002;100:246-58. 
15. Menezes J, Salgado RN, Acquadro F, Gómez-López G, Carralero MC, Barroso A, Mercadillo F, 
Espinosa-Hevia L, Talavera-Casañas JG, Pisano DG, Alvarez S, Cigudosa JC. ASXL1, TP53 and 
IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia. 
Blood Cancer J 2013;3:e157. 
 
 
 
 
  
 
 
FIGURE LEGENDS 
 
Figure 1.  Mutant p53 cooperates with FLT3-ITD in the pathogenesis of myeloid leukemia. (a) FLT3ITD/+ 
and p53R248W/+FLT3ITD/+ mice show decreased survival compared to p53+/+ mice (n=11, p53+/+; n=11, 
FLT3ITD/+; n=12, p53R248W/+FLT3ITD/+, **p<0.01, ****p<0.0001). (b) Disease spectrums in FLT3ITD/+ and 
p53R248W/+FLT3ITD/+ mice were determined by pathological analysis of bone marrow, spleen, liver, and 
peripheral blood (n=9, FLT3ITD/+; n=12, p53R248W/+FLT3ITD/+). (c) Representative H&E (20X) images of 
bone marrow, spleen, liver and peripheral blood smears from FLT3ITD/+ mice with MPN and 
p53R248W/+FLT3ITD/+ mice with CML. (d) Spleen weight of p53+/+, FLT3ITD/+, and p53R248W/+FLT3ITD/+ 
mice. Mean values (±SEM) are shown (n=12, p53+/+; n=12, FLT3ITD/+; n=17, p53R248W/+FLT3ITD/+, 
*p<0.05).   
 
Figure 2. Mutant p53 enhances the self-renewal potential of FLT3-ITD+ LICs.  (a) Serial replating assays 
of bone marrow cells from young p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice.  Mean 
values (±SD) are shown (n=3, *p<0.05, ****p<0.0001). (b) p53R248W enhances the repopulating potential 
of FLT3ITD/+ hematopoietic cells. Percentage of donor-derived (CD45.2+) cells in the peripheral blood of 
primary recipient mice post-transplantation, measured at 4-week intervals. Mean values (±SEM) are 
shown (n=7, ***p<0.001). (c) The percentage of donor-derived cells in the peripheral blood of secondary 
recipient mice. Mean values (±SEM) shown, (n=7, p53R248W/+ vs FLT3ITD/+ and FLT3ITD/+ vs 
p53R248W/+FLT3ITD/+, ****p<0.0001). (d) Western blot analysis of activated and total FAK, STAT5, AKT, 
and ERK protein levels in p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mononuclear cells 
differentiated into macrophage progenitors. Loading controls GAPDH and Vinculin are also shown.  
Quantification of phosphorylated proteins was calculated relative to total protein level and is displayed 
above each respective phospho-protein.     
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Supplemental Methods 
Mice  
FLT3-ITD knock-in mice were obtained from the Jackson Laboratory (Lee et al., 2007). The humanized 
mutant p53 knock-in mice (p53R248W/+) have been backcrossed to the C57BL6 background for at least 8 
generations (Chen et al., 2018). Wild type C57BL/6 (CD45.2+), B6.SJL (CD45.1+) and F1 mice (CD45.2+ 
CD45.1+) mice were obtained from an on-site core breeding colony. All mice were maintained in the 
Indiana University Animal Facility according to IACUC-approved protocols.  
Flow Cytometry  
Flow cytometry analysis of hematopoietic stem and progenitor cells was performed as described 
previously (Liu et al., 2009). Murine hematopoietic stem and progenitor cells were identified and 
evaluated by flow cytometry using a single cell suspension of bone marrow mononuclear cells (BMMCs). 
Hematopoietic stem and progenitors are purified based upon the expression of surface markers. Bone 
marrow (BM) cells were obtained from femurs by flushing cells out of the bone using a syringe and 
phosphate-buffered saline (PBS) with 2mM EDTA. Red blood cells (RBCs) were lysed by RBC lysis 
buffer (eBioscience) prior to staining. Experiments were performed on FACS LSR IV cytometers (BD 
Biosciences) and analyzed by using the FlowJo Version 9.3.3 software (TreeStar). 
Serial Replating Assays 
Clonogenic progenitors were determined in methylcellulose medium (MethoCult GF M3434, StemCell 
Technologies) with cytokines (SCF, TPO, EPO, IL-3 and GM-CSF) using 2 x 104 BMMCs per well (6-
well plate). Colonies were scored after 7 days of the initial culture, and all cells were collected and washed 
twice in phosphate-buffered saline. Subsequently cells were cultured at 2 x104 per well in the same 
medium. Colony scoring and replating were repeated every 7 days for at least two times, or until no 
colonies were observed in the cultures.  
  
 
Transplantation  
For the competitive repopulation assays, we injected 5 x 105 BM cells from p53+/+, p53R248W/+, FLT3ITD/+ 
and p53R248W/+FLT3ITD/+ mice (CD45.2+) plus 5 x 105 competitor BM cells (CD45.1+) into lethally 
irradiated (11Gy)  F1 mice (CD45.1+CD45.2+). Peripheral blood was obtained by tail vein bleeding every 
4-week after transplantation, RBC lysed, and the PB mononuclear cells stained with anti-CD45.2 FITC 
and anti-CD45.1 PE, and analyzed by flow cytometry. 16 weeks following transplantation, bone marrow 
cells from recipient mice were analyzed to evaluate donor chimerism in bone marrows. For secondary 
transplantation, 3 x 106 BM cells from mice reconstituted with p53+/+, p53R248W/+, FLT3ITD/+ and 
p53R248W/+FLT3ITD/+ BM cells were injected into lethally irradiated F1 mice (CD45.1+CD45.2+).  
Western Blot Analysis 
Bone marrow mononuclear cells from p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice were 
differentiated into macrophage progenitors with 10ng/ml M-CSF for 7-10 days.  Total cell lysates were 
collected, run on SDS-PAGE gels, and transferred to PVDF membrane.  Blots were probed with indicated 
primary antibody [p-FAK(Cell Sig. #3283), T-FAK(BD #610087), p-STAT5(Cell Sig. #9351), T-
STAT5(Cell Sig. #9363), p-AKT(Cell Sig. #9271), T-AKT(Cell Sig. #4691 ), p-ERK(Cell Sig. #9101), 
T-ERK(Cell Sig. #9102), FLT3 (Cell Signaling. #3462S), GAPDH(Santa Cruz #sc-32233), or 
Vinculin(sc-73614)] and incubated with secondary antibody, and imaged. 
Tissue Specimens 
All mice tissue samples were collected following a detailed LARC approved lab animal protocol, and 
were approved by the Indiana University School of Medicine Institutional Animal Care and Use 
Committee and adhered to all standards set forth in the ARVO Statement for the Use of Animals in 
Research. 
Tissue Processing 
  
In the histology study, all mice tissues were fixed in 10% neutral buffered formalin at 4°C for 24 hours 
following tissue processing, and then embedded in paraffin. Five-micrometer sections were stained for 
routine H&E. 
Pathology Scoring 
The lymphomas were sub classified into the following groups based on the St. Jude’s pathology 
classification of mouse lymphomas (Ward JM et al., 2012; Frith CH et al., 1993): 1: Diffuse Large B 
Cell Lymphoma involving multiple organs, 2: Thymic Lymphoma (usually associated with thymic and 
around the heart), and 3: Follicular Lymphoma, seen as a diffuse proliferation of lymphocytes in the 
white pulp area in the spleen. 
 
Myeloid proliferations include a wide range of disease, those similar to human disease at one end to 
subtle increases in the splenic nonlymphoid hematopoietic cells in genetic engineered mice at the other 
end. These can progress to leukemias. The mouse myeloproliferative disease is broken down into two 
subclassisfication, one in genetic engineered mice and in naturally occurring mice.  This is characterized 
by the combination of the following: A. Erythrocytosis, leukocytosis of myeloid cells, and/or 
thrombocytosis/circulating micromegakaryocytes; B. Increased in non-lymphoid hematopoietic cells in 
the spleen and bone marrow. Chronic myeloid leukemia (CML) in the mouse is a progression of 
myeloproliferative disease and is characterized by at least 20% immature blast cells with moderate 
differentiation and neutrophilic in blood, spleen, and or bone marrow (Kogan et al., Blood, 2002). 
 
The leukemia were classified by the following criteria:  1. Presence of large lymphocytes in the blood 
vessel lumens and/or vascular channels in the following organs examined. 2. Liver, lung, and kidney 
(blood vessels) and 3. Bone marrow and spleen (vascular channels).  
 
  
The MPN were classified as follows:  1) myeloid proliferation in the bone marrow, spleen and liver. 2) 
Myelofibrosis in the bone marrow.  This was composed of a proliferative infiltrate of mononuclear cells 
with features of blast and immature myeloid cells in the bone marrow, liver, and spleen. 
 
All histology slides were hand read by a pathologist and the cause of death was determined. All images 
obtained were scanned using Aperio Whole Slide Digital Imaging Platform. 
 
Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 6 software (GraphPad software, Inc). All data 
are presented as mean ± standard error of the mean (SEM). The sample size for each experiment are 
included in the figure legends. Statistical analyses were performed using unpaired, two-tailed Student’s t 
test where applicable for comparison between two groups, and a One-way ANOVA test or Two-way 
ANOVA was used for experiments involving more than two groups. Survival curves were tested using 
Geham-Breslow-Wilcoxon test and those P-values were then tested using ‘analyze stack of P values’ to 
check significance. Statistical significance was defined as *p< 0.05; **p < 0.01; ***p < 0.001; ****p < 
0.0001; ns, not significant. 
 
Supplementary Figure Legends 
Figure S1.   
(a) Recipient mice repopulated with FLT3ITD/ITD and p53R248W/+FLT3ITD/ITD bone marrow cells show 
significantly reduced survival compared to that of the p53+/+ cells (n=6, p53+/+; n=4, FLT3ITD/ITD; and n=6, 
p53R248W/+FLT3ITD/ITD mice, **p<0.01). (b) Disease spectrums in FLT3ITD/ITD and p53R248W/+FLT3ITD/ITD 
whole bone marrow transplant recipients were determined by pathological analysis of bone marrow, 
spleen, liver, and peripheral blood (n=4, FLT3ITD/ITD; n=6, p53R248W/+FLT3ITD/ITD mice). (c) Peripheral 
white blood cell (WBC) counts in p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice. Mean 
values (±SEM) are shown (n=6). (d) Bone marrow cell numbers of young p53+/+, p53R248W/+, FLT3ITD/+ 
  
and p53R248W/+FLT3ITD/+ mice. Mean values (±SEM) are shown (n=6). (e) Spleen weight of young p53+/+, 
p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice. Mean values (±SEM) are shown (n=8).  
 
Figure S2. (a) Frequency of LT-HSCs (CD48-CD150+LSKs), ST-HSCs (CD48-CD150-LSKs), MPPs 
(CD48+CD150-LSKs) and LSKs in the BM of young p53+/+, p53R248W/+, FLT3ITD/+ and 
p53R248W/+FLT3ITD/+ mice. Mean values (±SEM) are shown (n=8, *p<0.05, **p<0.01, ***p<0.001). (b) 
The frequency of myeloid progenitor cells (Lin-Kit+), CMPs (Lin−Sca1−Kit+FcγRII/IIIlowCD34high), GMPs 
(Lin−Sca1−Kit+FcγRII/IIIhighCD34high), and MEPs (Lin−Sca1−Kit+FcγRII/IIIlowCD34low) in the bone 
marrow of young p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice. Mean values (±SEM) are 
shown (n=8, *p<0.05, **p<0.01, ****p<0.0001. (c) The frequency of common lymphoid progenitors 
(CLPs) in the bone marrow of young p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice. Mean 
values (±SEM) are shown (n=5).  (d) Cell cycle status of LSK cells from young p53+/+, p53R248W/+, 
FLT3ITD/+ and p53R248W/+FLT3ITD/+ mice was determined by flow cytometry analysis. Mean values 
(±SEM) are shown (n=4, *p<0.05). (e) Peripheral white blood cell counts in recipient mice at 16 weeks 
following bone marrow transplantation. Mean values (±SEM) shown (n=7).  (f) The frequency of donor-
derived LSKs, LT-HSCs, ST-HSCs, and MPPs in the bone marrow of primary recipient mice 16 weeks 
following transplantation.  Mean values (±SEM) shown (n=7, *p<0.05, ***p<0.001).   
 
Figure S3.  (a) The frequency of donor-derived GMPs, CMPs, and MEPs in the bone marrow of primary 
recipient mice 16 weeks following transplantation.  Mean values (±SEM) shown (n=7, **p<0.01). (b) 
Spleen weight of recipient mice at 16 weeks following bone marrow transplantation. Mean values (±SEM) 
shown (n=7). (c) Western blot analysis of FLT3 in p53+/+, p53R248W/+, FLT3ITD/+ and p53R248W/+FLT3ITD/+ 
mononuclear cells differentiated into macrophage progenitors. Loading controls GAPDH and Vinculin 
are also shown.  (d) ERK inhibitor treatment decreased the replating potential of p53R248W/+, FLT3ITD/+ 
and p53R248W/+FLT3ITD/+ bone marrow cells. Mean values (±SD) are shown (n=3, *p<0.05, **p<0.01). 
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